Corrigendum to “Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies” [J Liq Biopsy, 10 (2025), 100442]
Institutions
Humanitas University (IT)
Harvard University (US)
Washington University in St. Louis (US)
The Ohio State University Wexner Medical Center (US)
Corrigendum to “Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies” [J Liq Biopsy, 10 (2025), 100442]
Journal
The Journal of Liquid Biopsy
Topics
Cancer Genomics and Diagnostics
article
Corrigendum to “Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies” [J Liq Biopsy, 10 (2025), 100442]
article en
Abstract
No abstract available for this paper.
Publication Tag
The Journal of Liquid BiopsyVol. 10
Institutions
Humanitas University (IT), Harvard University (US), Washington University in St. Louis (US), The Ohio State University Wexner Medical Center (US), Massachusetts General Hospital (US), Guardant (United States) (US)